Share your insights

Help us by sharing what content you've recieved in your exams


Polycythaemia

Background knowledge ๐Ÿง 

Definition

  • Polycythaemia refers to an increased red blood cell mass in the body.
  • It is generally defined as a haemoglobin concentration >185 g/L in men and >165 g/L in women.
  • It can be primary (due to bone marrow pathology) or secondary (due to external factors).

Epidemiology

  • Polycythaemia is relatively rare, with an incidence of about 2-3 per 100,000 people annually.
  • More common in men than women.
  • Primary polycythaemia (Polycythaemia vera) typically presents in middle age (50-70 years).
  • Secondary polycythaemia is more prevalent and can occur at any age depending on the underlying cause.

Aetiology and Pathophysiology

  • Primary polycythaemia (Polycythaemia vera) is caused by a mutation in the JAK2 gene leading to unregulated red blood cell production.
  • Secondary polycythaemia results from increased erythropoietin (EPO) production due to hypoxia, tumours, or other causes.
  • Hypoxic causes include chronic lung disease, smoking, and living at high altitude.
  • Non-hypoxic causes include renal disease, hepatic tumours, and paraneoplastic syndromes.

Types

  • Polycythaemia Vera (Primary Polycythaemia): Characterised by the overproduction of red blood cells due to a bone marrow disorder.
  • Secondary Polycythaemia: Caused by external factors like hypoxia or tumours leading to increased EPO.
  • Relative Polycythaemia: Apparent increase in red blood cells due to decreased plasma volume, often due to dehydration or diuretics.

Clinical Features ๐ŸŒก๏ธ

Symptoms

  • Headaches and dizziness.
  • Pruritus, especially after a hot shower (common in Polycythaemia vera).
  • Visual disturbances.
  • Fatigue and weakness.
  • Dyspnoea.
  • Night sweats and weight loss (more specific to Polycythaemia vera).

Signs

  • Plethora (ruddy complexion).
  • Hypertension.
  • Splenomegaly (particularly in Polycythaemia vera).
  • Gout (due to increased cell turnover).
  • Erythromelalgia (burning pain in hands/feet).
  • Thrombosis or bleeding complications.

Investigations ๐Ÿงช

Tests

  • Full blood count (FBC): Elevated haemoglobin, haematocrit, and red cell mass.
  • Serum erythropoietin levels: Low in Polycythaemia vera, high in secondary polycythaemia.
  • JAK2 mutation analysis: Positive in over 95% of Polycythaemia vera cases.
  • Oxygen saturation: To exclude hypoxic causes.
  • Abdominal ultrasound: To check for splenomegaly and rule out renal causes.
  • Bone marrow biopsy: May be performed to assess bone marrow cellularity in unclear cases.

Management ๐Ÿฅผ

Management

  • Venesection: First-line treatment in Polycythaemia vera to reduce red cell mass.
  • Aspirin: Low-dose aspirin to reduce thrombotic risk.
  • Cytoreductive therapy: Hydroxycarbamide (hydroxyurea) is used in high-risk patients.
  • Treat underlying cause in secondary polycythaemia (e.g., oxygen therapy for hypoxia).
  • JAK inhibitors: For patients with Polycythaemia vera resistant to first-line treatments.

Complications

  • Thrombosis: Increased risk of both arterial and venous thrombosis.
  • Myelofibrosis: A potential progression of Polycythaemia vera.
  • Acute leukaemia: Rare, but possible transformation from Polycythaemia vera.
  • Bleeding complications: Paradoxical risk due to platelet dysfunction.
  • Gout: Due to increased uric acid from cell turnover.

Prognosis

  • Polycythaemia vera is a chronic condition with variable prognosis.
  • With treatment, patients can live for many years but require ongoing monitoring.
  • Risk of complications (e.g., thrombosis, myelofibrosis) impacts overall prognosis.
  • Survival rates have improved with better management strategies.

Key Points

  • Polycythaemia involves an increased red blood cell mass and can be primary or secondary.
  • Key diagnostic tests include FBC, JAK2 mutation analysis, and serum EPO levels.
  • Management focuses on reducing red cell mass and preventing complications, particularly thrombosis.
  • Polycythaemia vera is associated with specific complications like myelofibrosis and acute leukaemia.
  • Regular follow-up is crucial to monitor disease progression and manage complications.

No comments yet ๐Ÿ˜‰

Leave a Reply